首页> 美国卫生研究院文献>OncoTargets and therapy >Clinical Outcomes and Safety of Apatinib Mesylate in the Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Patients Who Progressed After Standard Therapy and Analysis of the KDR Gene Polymorphism

【2h】

Clinical Outcomes and Safety of Apatinib Mesylate in the Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Patients Who Progressed After Standard Therapy and Analysis of the KDR Gene Polymorphism

机译：甲磺酸阿帕替尼治疗标准疗法后进展的晚期非鳞状非小细胞肺癌的临床疗效和安全性及KDR基因多态性分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

This study investigated the clinical outcomes and safety of apatinib mesylate in the treatment of advanced non-squamous non-small cell lung cancer (NSCLC) in patients who progressed after standard therapy, and analyzed the ( ) gene polymorphism.

机译：这项研究调查了甲磺酸阿帕替尼在标准治疗后进展的晚期晚期非鳞状非小细胞肺癌（NSCLC）中的临床疗效和安全性，并分析了（）基因多态性。

著录项

期刊名称 OncoTargets and therapy
作者
Zi-Zheng Song; Li-Fen Zhao; Jing Zuo; Zhi-Song Fan; Long Wang; Yu-Dong Wang;
展开▼
作者单位

展开▼
年(卷),期 2020(13),-1
年度 2020
页码 -1
总页数 11
原文格式 PDF
正文语种
中图分类应用微生物学;肿瘤学;
关键词
non-small cell lung cancer; apatinib mesylate;

机译：非小细胞肺癌;甲磺酸阿帕替尼;

相似文献

外文文献
中文文献
专利

1. Clinical Outcomes and Safety of Apatinib Mesylate in the Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Patients Who Progressed After Standard Therapy and Analysis of the KDR Gene Polymorphism [J] . Zi-Zheng Song, Li-Fen Zhao, Jing Zuo, OncoTargets and therapy . 2020,第2期

机译：Apatinib甲磺酸盐的临床结果和安全性在治疗后患者前进的非鳞状非小细胞肺癌，分析KDR基因多态性分析
2. XPG genetic polymorphisms and clinical outcome of patients with advanced non-small cell lung cancer under platinum-based treatment: a meta-analysis of 12 studies [J] . Xiang Tianxin, Kang Xiuhua, Gong Zhenghua, Cancer chemotherapy and pharmacology. . 2017,第4期

机译：基于铂治疗下的晚期非小细胞肺癌患者的XPG遗传多态性及临床结果：12项研究的META分析
3. Genetic polymorphisms of GSTP1, XRCC1, XPC and ERCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer patients of Bangladesh [J] . Bushra Most Umme, Rivu Sanzana Fareen, Sifat Ali Ehsan, Molecular biology reports . 2020,第9期

机译：GSTP1，XRCC1，XPC和ERCC1的遗传多态性：孟加拉国先进非小细胞肺癌患者铂金疗法临床疗效预测
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. Individualized treatments for patients with advanced non-small cell lung cancer: A genetic approach [D] . Ferrao, Amanda. 2013

机译：晚期非小细胞肺癌患者的个体化治疗：一种遗传方法
6. Association between Gene Expression Profiles and Clinical Outcome of Pemetrexed-Based Treatment in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: Exploratory Results from a Phase II Study [O] . Dean A. Fennell, Scott P. Myrand, Tuan S. Nguyen, -1

机译：晚期非鳞状非小细胞肺癌患者基因表达谱与基于培美曲塞治疗的临床结果之间的关联：II期研究的探索性结果
7. >Clinical Outcomes and Safety of Apatinib Mesylate in the Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Patients Who Progressed After Standard Therapy and Analysis of the KDR Gene Polymorphism [O] . Zi-Zheng Song, Li-Fen Zhao, Jing Zuo, 2020

机译：>在标准治疗后进展的患者治疗晚期非鳞状非小细胞肺癌中的临床结果和安全性，分析 Kdr 基因多态性

1. 甲磺酸阿帕替尼三线治疗晚期EGFR野生型、非鳞、非小细胞肺癌的临床研究 [J] . 刘岩峰 . 现代医学与健康研究 . 2018,第007期

2. 晚期非鳞非小细胞肺癌一线诱导化疗后贝伐单抗联合培美曲塞维持治疗的疗效和安全性 [J] . 刘晓晴 ,李锋 . 循证医学 . 2014,第001期

3. 甲磺酸阿帕替尼片单药三线治疗VEGFR-2高表达晚期非鳞NSCLC患者的近期疗效和安全性体会 [J] . 王婷 ,马惠文 ,王东林 . 实用肿瘤杂志 . 2018,第5期

4. 免疫检查点抑制剂联合抗血管生成药物治疗晚期非鳞状细胞非小细胞肺癌的研究进展 [J] . 许子宜 ,李峻岭 . 癌症进展 . 2019,第018期

5. 抗血管生成药物治疗晚期非鳞状非小细胞肺癌的研究进展 [J] . 王亚磊 . 癌症进展 . 2018,第010期

6. 甲磺酸阿帕替尼治疗晚期非鳞非小细胞肺癌随机、双盲、安慰剂对照、多中心Ⅱ期临床研究 [C] . 张力 ,史美祺 ,黄诚 . 第十五届全国临床肿瘤学大会暨2012年CSCO学术年会 . 2012

7. 阿帕替尼用于一线治疗进展后晚期非鳞非小细胞肺癌的疗效和生存分析 [A] . 王学敏 . 2018

1. 用于治疗晚期非小细胞肺癌的采用靶向的TGF-β抑制的组合疗法 [P] . 中国专利： CN112638374A . 2021-04-09

2. 伊曲康唑异构体在制备治疗鳞状非小细胞肺癌药物中的应用 [P] . 中国专利： CN111603470A . 2020-09-01

3. method for determining if ec145 is indicated for the treatment of a patient with an ovarian tumor or a lung tumor; method for predicting a response from an ovarian tumor or a lung tumor of a patient to ec145 therapy; method of treating platinum-resistant ovarian cancer in a patient in need; use of ec145 in combination with pegylated liposomal doxorubicin; use of ec145 for the manufacture of a medicament; method for obtaining a clinical benefit compared to treatment with a therapeutic amount of pegylated liposomal doxorubicin in the treatment of platinum-resistant ovarian cancer in a patient in need thereof; method for selecting a patient for treatment; pharmaceutical composition; dosage unit, method for determining if a patient with a tumor has functionally active folate receptors present in the patient's tumor; method of treating a folate receptor expressing epithelial tumor in a patient in need thereof; and; method for obtaining a clinical benefit in the treatment of a folate recepto [P] . 外国专利： BR112012002064A2 . 2017-05-09

机译：确定ec145是否适合治疗卵巢肿瘤或肺肿瘤患者的方法;预测患者的卵巢肿瘤或肺肿瘤对ec145治疗的反应的方法;在有需要的患者中治疗铂耐药的卵巢癌的方法; ec145与聚乙二醇化阿霉素组合使用; ec145在制造药物中的用途;与治疗量的聚乙二醇化脂质体阿霉素治疗相比获得临床益处的方法，在有需要的患者中治疗铂耐药性卵巢癌;选择患者进行治疗的方法;药物组合物;剂量单位，用于确定患有肿瘤的患者是否具有存在于患者肿瘤中的功能活性叶酸受体的方法;在有需要的患者中治疗表达叶酸受体的上皮肿瘤的方法;和;治疗叶酸受体的临床方法

4. Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by non-small cell lung cancer patients [P] . 外国专利： US9434994B2 . 2016-09-06

机译：非小细胞肺癌患者预测表皮生长因子受体抑制剂临床疗效的方法

5. Methods for Providing Information to Assess Chemotherapy Responsiveness in Patients with Advanced Non-Squamous Lung Cancer [P] . 外国专利： JP2020153742A . 2020-09-24

机译：提供信息以评估晚期非鳞癌患者化疗反应性的方法

相关主题

Clinical Outcomes and Safety of Apatinib Mesylate in the Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Patients Who Progressed After Standard Therapy and Analysis of the KDR Gene Polymorphism

摘要

著录项

相似文献

相关主题

期刊订阅